Bruker and Evosep Announce Major Progress in Unbiased, Quantitative True Single-cell Proteomics

Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) and Evosep have announced advancements in high-sensitivity, true single-cell proteomics using a modified timsTOF Pro mass spectrometer and Evosep One chromatography system. A study by the Mann-group achieved identification of up to 1,500 protein groups from single HeLa cells. Innovative ultra low-flow methods demonstrated 10x higher sensitivity at 100 nL/min gradients. The new technologies enable better single-cell analysis, critical for clinical diagnostics and biomarker discovery, with commercialization planned for 2022.

Positive

• Achieved identification of up to 1,500 protein groups from single cells, enhancing sensitivity.
• New ultra low-flow methods provide 10x greater sensitivity, improving single-cell analysis.
• Innovations enable robust workflows for analyzing multiple single cells, enhancing throughput.

Negative

• None.

Bruker Corporation (Nasdaq: BRKR) and Evosep today announced major progress in high-sensitivity, quantitative true single-cell proteomics, using a modified timsTOF Pro mass spectrometer connected to an Evosep One low-flow chromatography system.

Figure 1: Evosep One LC and timsTOF Pro MS (Photo: Business Wire)

These advances have been demonstrated by the Mann-group in a paper by A. Brunner et al., which is now available on Bioarchive at https://www.biorxiv.org/content/10.1101/2020.12.22.423933v1. Key results include the first untargeted and unbiased analysis of true single cells achieving an identification depth of up to 1,500 protein groups from single FACS-sorted and individually digested HeLa cells. This remarkable sensitivity was achieved by the combined Evosep–timsTOF platform using crucial innovations.

Two new ultra low-flow methods on an otherwise unmodified Evosep One system offer 100 nL/min gradients that lead to approximately 10 times higher sensitivity than gradients at 1 µL/min, confirming theoretical expectations. These new nano-flow methods, using the Whisper™ flow technology, have the same low overhead as the other established Evosep One methods, and offer a throughput of either 20 or 40 samples per day. They make single-cell analysis robust, as shown by the analysis of 420 single cells that were analyzed on the same column. The workflow retrieved known and unexpected proteins changing abundance upon chemically arresting the cell cycle at discrete points.

Also crucial for achieving ultra-high true single-cell sensitivity was a new modified timsTOF mass spectrometer that included a new, brighter ion source with associated modified ion optics. These precommercial innovations on the timsTOF platform were combined with the newly developed dia-PASEF® ¹ scan mode, wherein a large percentage of all peptides are sampled in an unbiased manner. The study provided further evidence of the advantages of data-independent analysis (DIA) for short LC gradients or extremely low abundance samples, such as single cells. Even for these single cells, the quantitative reproducibility was high in this novel Evosep–timsTOF workflow.

The authors performed an in-depth comparison to cells analyzed by single-cell RNA sequencing by two different technologies, allowing them to distinguish technical vs. fundamental biological differences between the proteomes and transcriptomes. This revealed that single cells have stable core proteomes with sufficient protein copy numbers to permit meaningful quantitation, whereas the transcriptome appears to behave more randomly, presumably because of low copy numbers of many mRNA transcripts per cell.

The principal investigator behind the Bioarchive article, Professor Matthias Mann at the Max-Planck Institute of Biochemistry, stated: “The sensitivity and robustness to truly analyze single cell proteomes is becoming a practical reality. We are now able to routinely measure cohorts of single cells, and quantitatively assess single-cell states to reveal new cell biological information. The Evosep One and timsTOF Pro have been pivotal to enable and scale these true single cell measurements, making it also a suitable platform for single-cell proteomic biomarker discovery and quantitation work.”

Bruker’s Vice President of Proteomics, Dr. Gary Kruppa, noted: “I am very excited about the new quantitative, true single cell study. This is another great example of what the timsTOF platform can achieve, and a further cell biology breakthrough facilitated by the dia-PASEF method. We anticipate providing the new ultra-high sensitivity timsTOF technologies to early-access collaborators in the second half of 2021 on dedicated single-cell proteomics systems, and we plan for full commercialization in 2022.”

Dr. Nicolai Bache, a co-author on the study and Head of Applications at Evosep, concluded: “This type of robust single cell analysis is an important step towards enabling proteome analysis and digital pathology in everyday clinical diagnostics. We are very happy that the Evosep One stands to make a significant contribution to this promising new area.”

1. ‘diaPASEF: parallel accumulation-serial fragmentation combined with data-independent acquisition’, Meier F, Brunner AD, Frank M, Ha A, Bludau I, Voytik E, Kaspar-Schoenefeld S, Lubeck M, Raether O, Bache N, Aebersold R, Collins BC, Röst HL, Mann M, Nat Methods. 2020 Dec;17(12):1229-1236. doi: 10.1038/s41592-020-00998-0.

About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information: www.bruker.com.

About Evosep
Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than today’s alternatives. This calls for fast sample processing and because clinical samples, in the form of blood or biopsies, are much more crude, very robust protocols and consumables are also required. Read more about Evosep One and the two new nano-flow methods on www.evosep.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005248/en/

FAQ

What recent advancements has Bruker (BRKR) made in single-cell proteomics?

Bruker and Evosep announced significant progress in true single-cell proteomics using their modified systems, achieving unprecedented sensitivity and identification of protein groups.

How many protein groups can be identified from single HeLa cells with the new Bruker technology?

The new technology allows for identification of up to 1,500 protein groups from single FACS-sorted HeLa cells.

When is the full commercialization of Bruker's new technologies planned?

Full commercialization of the new ultra-high sensitivity timsTOF technologies is planned for 2022.

What is the significance of the new ultra low-flow methods developed by Bruker?

The ultra low-flow methods achieve 10 times higher sensitivity than traditional methods, improving the robustness and throughput of single-cell analyses.